Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-08-03, Stock:NVS, The news for the past five days is as follows:
2018-07-27: NEWS1: Antibiotics market wipes out 80 jobs at Peninsula company a month after its 1st drug approval.NEWS2: 1 week until the deadline for Disrupt SF 2018’s Hackathon + new sponsor prizes.NEWS3: Roche (RHHBY) 1H18 Revenues Up Y/Y on Solid New Drug Sales.NEWS4: Roche (RHHBY) 1H18 Revenues Up Y/Y on Solid New Drug Sales.NEWS5: Amgen (AMGN) Q2 Earnings & Sales Beat Estimates, View Up.NEWS6: Amgen (AMGN) Q2 Earnings & Sales Beat Estimates, View Up.NEWS7: Incyte (INCY) to Report Q2 Earnings: What's in the Cards?.NEWS8: Incyte (INCY) to Report Q2 Earnings: What's in the Cards?.NEWS9: Amgen (AMGN) Q2 Earnings & Sales Beat Estimates, View Up.NEWS10: The Swiss Stock Market Logged Modest Gains - LafargeHolcim In Focus.NEWS11: The Swiss Stock Market Logged Modest Gains - LafargeHolcim In Focus.NEWS12: The Swiss Stock Market.NEWS13: The Swiss Stock Market.NEWS14: Novartis' Sandoz Gets European Commission Approval For Biosimilar Hyrimoz.NEWS15: Novartis' Sandoz Gets European Commission Approval For Biosimilar Hyrimoz.NEWS16: Novartis: Tafinlar + Mekinist Combination Gets Positive CHMP Opinion.NEWS17: Novartis: Tafinlar + Mekinist Combination Gets Positive CHMP Opinion.
2018-07-30: NEWS1: How Celgene’s Otezla and Abraxane Did in Q2 2018.NEWS2: What's in the Cards for Conatus (CNAT) This Earnings Season?.NEWS3: What's in the Cards for Conatus (CNAT) This Earnings Season?.NEWS4: Novartis Reports EU Approval Of Aimovig - Quick Facts.NEWS5: Novartis Reports EU Approval Of Aimovig - Quick Facts.NEWS6: ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates.NEWS7: ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates.NEWS8: A Look at Celgene’s Financials in Q2 2018.NEWS9: A Look at Teva’s Earnings Estimates ahead of Q2 Results.NEWS10: Why Analysts Expect Teva’s Revenues to Fall in the Second Quarter.NEWS11: The Swiss Stock Market Dipped As Defensive Heavyweights Fall.NEWS12: The Swiss Stock Market Dipped As Defensive Heavyweights Fall.NEWS13: The Majority of Analysts Recommend a ‘Hold’ for Teva.NEWS14: The Swiss Stock Market.NEWS15: The Swiss Stock Market.NEWS16: European Medicines Agency's CHMP Says Yes To 7 Drugs, No To 1.NEWS17: European Medicines Agency's CHMP Says Yes To 7 Drugs, No To 1.
2018-07-31: NEWS1: Incyte (INCY) Earnings Miss, Revenues Beat Estimates in Q2.NEWS2: Incyte (INCY) Earnings Miss, Revenues Beat Estimates in Q2.NEWS3: Pfizer Beat Wall Street Analyst Estimates for Q2 2018 Earnings.NEWS4: Sanofi’s Q2 2018 Earnings: Sales and Profits Decline.NEWS5: 3 Biotech Stocks in Focus on Tuesday.NEWS6: What Lies in Store for Ligand (LGND) This Earnings Season?.NEWS7: What Lies in Store for Ligand (LGND) This Earnings Season?.NEWS8: The Swiss Stock Market Rose On Credit Suisse Strength.NEWS9: The Swiss Stock Market Rose On Credit Suisse Strength.
2018-08-01: NEWS1: More drugmakers build Brexit stockpiles as EU agency faces exodus.NEWS2: MorphoSys AG Posts Wider Loss In Q2 - Quick Facts.NEWS3: MorphoSys AG Posts Wider Loss In Q2 - Quick Facts.NEWS4: More drugmakers build Brexit stockpiles as EU agency faces exodus.NEWS5: Entresto and Aimovig: Long-Term Growth Drivers for Novartis.NEWS6: Sanofi, Novartis latest to stockpile drugs in case of no-deal Brexit.NEWS7: Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q2, Gilead&apos;s CEO to Exit.NEWS8: Pfizer, Inc. (PFE) Ex-Dividend Date Scheduled for August 02, 2018.NEWS9: Pfizer, Inc. (PFE) Ex-Dividend Date Scheduled for August 02, 2018.NEWS10: Key Growth Drivers of Novartis’s Innovative Medicines Business.
2018-08-02: NEWS1: Healthcare Bulls Get a Second Dose of Earnings-Driven Profits.NEWS2: Conatus' (CNAT) Q2 Loss Narrows, Revenues Lag Marginally.NEWS3: Conatus' (CNAT) Q2 Loss Narrows, Revenues Lag Marginally.NEWS4: Conatus&apos; (CNAT) Q2 Loss Narrows, Revenues Lag Marginally.NEWS5: Merck’s Keytruda Witnessed Solid Growth in First Half of 2018.NEWS6: Promacta, Tafinlar + Mekinist, Jakavi: NVS’s Oncology Portfolio.NEWS7: The Swiss Stock Market Dipped On Trade Worries.NEWS8: The Swiss Stock Market Dipped On Trade Worries.NEWS9: How Is Merck’s Diabetes and Women’s Health Business Positioned?.NEWS10: Novartis Is Focused on Advancing Its Oncology Portfolio in 2018.

Answer: Decrease